Table 2.
Posted results of first-line combination regimen trials for pembrolizumab, nivolumab, and atezolizumab in advanced NSCLC
| Identifier | Trials | Agent | Phase | Population | Arms | Biomarkers | ORR | mPFS | 1 year PFS rate |
mOS | 1 year OS rate | mDOR | Adverse Effects Rate (≥ grade 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02039674 | Keynote 021 | Pembrolizumab | II |
Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration |
Pembrolizumab + platinum | Regardless PD-L1 | 55.00% | 24 m | NA | NR | NA | NA | 39.00% |
| Platinum | 29.00% | 9.3 m | 21.1 m | 26.00% | |||||||||
| NCT02578680 | Keynote 189 | Pembrolizumab | III |
Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration |
Pembrolizumab + platinum | Regardless PD-L1 | 47.60% | 8.8 m | 34.10% | NR | 69.20% | 11.2 m | 67.20% |
| Platinum | 18.90% | 4.9 m | 17.30% | 11.3 m | 49.90% | 7.8 m | 65.80% | ||||||
| NCT02775435 | Keynote 407 | Pembrolizumab | III | Untreated metastatic, squamous NSCLC | Pembrolizumab + platinum | Regardless PD-L1 | 57.90% | 6.4 m | NA | 15.9 m | 65.20% | 7.7 m | 69.80% |
| platinum | 38.40% | 4.8 m | NA | 11.3 m | 48.30% | 4.8 m | 68.20% | ||||||
| NCT02477826 | Checkmate 227 | Nivolumab | III |
Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration |
Nivolumab + platinum | TMB ≥ 10mut/Mb | 60.50% | NA | 27.00% | NA | NA | NA | NA |
| Nivolumab + ipilimumab | 45.30% | 7.2 m | 45.00% | 31.20% | |||||||||
| Platinum | 27.00% | 5.4 m | 13.20% | 36.10% | |||||||||
| NCT02657434 | Impower 131 | Atezolizumab | III | Treatment-naïve Stage IV squamous NSCLC | Atezolizumoab + carboplatin | ITT population | 49.00% | 6.3 m | 24.00% | 14.0 m | 55.60% | NA | 69.00% |
| Carboplatin | 41.00% | 5.6 m | 12.00% | 13.9 m | 56.80% | 58.00% | |||||||
| 2NCT02657434 | Impower132 | Atezolizumab12 | III |
Non-squamous NSCLC Without EGFR/ALK alterationUntreated metastatic |
Atezolizumoab + carboplatin | ITT population | 47.00% | 7.6 m | 33.70% | 18.1 m | 59.60% | 10.1 m | 69.00% |
| Carboplatin | 32.00% | 5.2 m | 13.6 m | 59.00% | |||||||||
| NCT02659059 | Checkmate 568 | Nivolumab | II |
Untreated metastatic Non-squamous NSCLC Without EGFR/ALK alteration |
Nivolumab plus low-dose ipilimumab | PD-L1 < 1% | 41.00% | 6.8 m | 52%a | NA | NA | NA | 29.00% |
| PD-L1 ≥ 1% | 15.00% | 2.8 m | 32%a | ||||||||||
| TMB ≥ 10 mut/Mb | 44.00% | 7.1 m | 55%a | ||||||||||
| TMb < 10 mut/Mb | 12.00% | 2.6 m | 31%a |
Combination strategies may help patients overcome NSCLC resistance that ICI monotherapy face with
ORR objective response rate, PFS Progression Free Survival, OS overall survival, DOR Duration of Response, ITT intend to treat, TMB tumor mutation burden
a6-month PFS rate